This continuing education self-study monograph, “Adult Glioblastoma: Optimal Approaches to a Challenging Diagnosis,” is certified for physicians, pharmacists, and registered nurses.
To Download
MEDIUM: MONOGRAPH
Release date: August 3, 2009
ACPE release date: June 17, 2009
Continuing education credit is no longer available for this activity.
CONTENTS
- Continuing Education Information
- Introduction
- Glioblastoma: A Broad Overview
- Current Treatment Strategies
- Investigational Agents for Newly Diagnosed Glioblastoma
- Salvage Therapy for Glioblastoma
- Overcoming Treatment Barriers
- Conclusion
- References
- Learning Assessment
- Evaluation Form
FACULTY REVIEWER
Marc C. Chamberlain, MD
Professor, Neurology & Neurological Surgery
Department of Neurology & Neurological Surgery
Chief, Division of Neuro-Oncology
University of Washington
Affiliate Investigator
Fred Hutchinson Cancer Research Center
Seattle, Washington
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, neuro-oncologists, neurologists, neurosurgeons, pharmacists, oncology nurses, and registered nurses involved in the care of adult patients with glioblastoma.
PURPOSE
This activity is intended to provide healthcare professionals with clinical information that will contribute to improving competence in the treatment or management of adult patients with glioblastoma.
STATEMENT OF NEED
Glioblastomas (GBMs) account for approximately 50% of all gliomas of the central nervous system.1 GBMs are are associated with genetic alterations of several critical signaling and tumor suppressor pathways.2 Presenting symptoms of GBMs are most often those of altered mental status, including personality change or language disturbance, lateralized weakness, seizure, or headache. Confirmation of an intracranial mass lesion (and a presumptive diagnosis of GBM) is initially obtained by noninvasive brain imaging, most often magnetic resonance imaging with contrast administration. Nonetheless, diagnosis requires pathologic confirmation obtained by biopsy or resective surgery.
Temozolomide-based chemotherapy is used both with concurrent involved-field radiotherapy and after completion of radiotherapy. Despite improvement in overall survival of newly diagnosed GBM, treatment remains noncurative, with more than 50% of patients dying of disease progression within 18 months of diagnosis.3,4 There is hope for improving these outcomes as healthcare professionals gain a better understanding of the molecular biology of GBMs and utilize GBM-specific targeted therapies more frequently.
1Central Brain Tumor Registry of the US (CBTRUS) data, 1998–2002.
2The Cancer Genome Atlas Research Network. Nature. 2008;455:1061-1068.
3Fine HA. In: DeVita VT Jr., et al. Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins;
2000:1834-1897.
4National Cancer Institute. Available at: www.cancer.gov. Accessed March 30, 2009.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe the epidemiology of adult glioblastoma
- Outline the role of surgery, radiation therapy, and chemotherapy in the initial treatment of adult glioblastoma
- Review treatment options for recurrent glioblastoma
- Identify treatment challenges in special patient populations
- Review emerging therapies for adult glioblastoma
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of continuing education (CE) activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
CONTINUING EDUCATION
METHOD OF PARTICIPATION
There are no fees for participating and receiving continuing education (CE) credit for this activity. During the period of August 3, 2009, through August 3, 2010, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the Learning Assessment by recording the best answer to each question in the "Learning Assessment Answers" box on the Evaluation form, 4) complete the Evaluation form, and 5) mail or fax the Evaluation form with the Learning Assessment answers to Postgraduate Institute for Medicine. You may also complete the Learning Assessment online at www.cmeuniversity.com. Click on "Find Post-Test/Evaluation by Course" on the navigation menu, and search by project ID 6582. Upon successfully completing the Learning Assessment and Evaluation form, your certificate will be made available immediately.
Participants must receive a score of at least 70% on the Learning Assessment and must complete and submit the Evaluation form to successfully complete this activity. Participants who successfully complete this activity will be issued a statement of credit via US mail in 4 to 6 weeks.
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Postgraduate Institute for Medicine (PIM) and Robert Michael Educational Institute LLC (RMEI). PIM is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
CREDIT DESIGNATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.2 contact hours
(0.12 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 809-999-09-095-H01-P).
If you have received credit for UAN 809-999-09-073-L01-P, you are not eligible for this activity.
NURSING CONTINUING EDUCATION
CREDIT DESIGNATION
This educational activity for 1.2 contact hours is provided by Postgraduate Institute for Medicine (PIM).
CNA/ANCC
PIM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CALIFORNIA BOARD OF REGISTERED NURSING
PIM is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.4 contact hours.
STATEMENT OF SUPPORT
This activity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine, and is supported by an educational grant from Schering-Plough.
FEE INFORMATION
There is no fee for this educational activity.
|
Additional educational activities offered by Robert Michael Educational Institute LLC can be found at www.RMEI.com or by calling toll-free to 866-770-RMEI.
